KITE-753 Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for KITE-753 comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Hematologic Neoplasms. Most recent publication: Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2., J Hematol Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.
    Muñoz J, Locke FL, Reagan PM, et al. · J Hematol Oncol · 2026
    PubMed: PMID 42036693 · NCT05041309 · Hematologic Neoplasms

Publications by year

20262026: 1 publications.

2026
1

Publications by indication

Hematologic Neoplasms (1)

  • Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.
    J Hematol Oncol · 2026 · PMID 42036693 · NCT05041309

Publications by journal

All KITE-753 publications (1)

2026 (1 paper)

  1. Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.
    Muñoz J, Locke FL, Reagan PM, et al. · J Hematol Oncol · 2026 · Derived
    PubMed: PMID 42036693 · NCT05041309 · Hematologic Neoplasms

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).